Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine

International Journal of Molecular Sciences

Vittorio Simeon²  Katia Todoerti²  Francesco La Rocca²  Antonella Caivano²  Stefania Trino²  Marta Lionetti³  Luca Agnelli³  Luciana De Luca²  Ilaria Laurenzana²  Antonino Neri³  Pellegrino Musto¹ 

[1] Scientific Direction, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture 85028, Italy; E-Mail:;Laboratory of Pre-Clinical and Translational Research, Reference Cancer Center of Basilicata, Scientific Institute of Hospitalization and Treatment, Rionero in Vulture 85028, Italy; E-Mails:;Department of Clinical Sciences and Community Health, University of Milan and Hematology, Fondazione Cà Granda, Ospedale Maggiore Policlinico, Milan 20122, Italy; E-Mails:

关键词: plasma cell leukemia;    molecular profiling;    risk stratification;    pharmacogenetics;    precision medicine;   

DOI  :  10.3390/ijms160817514

来源: mdpi

【 摘 要 】

Primary plasma cell leukemia (pPCL) is a rare and aggressive variant of multiple myeloma (MM) which may represent a valid model for high-risk MM. This disease is associated with a very poor prognosis, and unfortunately, it has not significantly improved during the last three decades. New high-throughput technologies have allowed a better understanding of the molecular basis of this disease and moved toward risk stratification, providing insights for targeted therapy studies. This knowledge, added to the pharmacogenetic profile of new and old agents in the analysis of efficacy and safety, could contribute to help clinical decisions move toward a precision medicine and a better clinical outcome for these patients. In this review, we describe the available literature concerning the genomic characterization and pharmacogenetics of plasma cell leukemia (PCL).

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.